Practice Management News

The FDA’s Center for Devices and Radiological Health finalized the guidance on Medical Device Data Systems and confirmed their intention not to enforce regulations on technologies that receive, transmit, store or display data from medical devices. The overall aim is to create an impetus for the development of new technologies to better use and display the data, according to the FDA.

Nexavar and transarterial chemoembolization combination therapy for advanced hepatocellular carcinoma was well tolerated by elderly patients, according to study data.

Researchers discovered a known lack in retention of women in academic medicine and gender inequity in compensation as a result of interviews with leadership at medical schools nationwide.

In a cohort of patients coinfected with HIV and hepatitis C virus, a majority were required to undergo an antiretroviral therapy switch before beginning treatment with Olysio, according to data from a poster presentation at CROI 2015.

After treatment with Harvoni for hepatitis C virus infection, high rates of sustained virologic response were observed in treatment-naive patients coinfected with hepatitis C virus infection and HIV, according to data from a phase 2b pilot study.

Valeant Pharmaceuticals International, Inc., and Salix Pharmaceuticals, Ltd., have announced an agreement that Valeant will acquire the outstanding common stock of Salix for a $158 per share cash transaction, representing an estimated $14.5 billion total enterprise value, according to a press release.

Updated results from the HEAT Study indicated an increased overall survival rate among patients with primary liver cancer when treated with ThermoDox combined with radiofrequency ablation, according to a press release.

The complex design of endoscopic retrograde cholangiopancreatography duodenoscopes may cause challenges for effective cleaning and disinfection, according to an FDA safety communication released today.

Lab-grown liver cells derived from induced pluripotent stem cells may allow for personalized testing on antimalarial drugs and vaccines, according to recent data.

In the MATTERHORN clinical trial, prior partial and null responders treated with a regimen of danoprevir/ritonavir, mericitabine plus pegylated interferon alfa-2a/ribavirin achieved a sustained virologic response after 24 weeks of treatment.